[1] 顾东风,Jiang H,吴锡贵,等. 中国成年人主要死亡原因及其危险因素[J]. 中国慢性病预防与控制, 2006;14(3):149-154. [2] Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics - 2013 update: a report from the American Heart Association[J]. Circulation,2013,127(1): e6. [3] Joseph J, Velasco A, Hage FG, et al. Guidelines in review: Comparison of ESC and ACC/AHA guidelines for the diagnosis and management of patients with stable coronary artery disease[J]. J Nucl Cardiol, 2017,77(10):1007-1012. [4] Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA guideline for coronary artery bypass graft surgery: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[J]. J Thorac Cardiovasc Surg, 2012,143(1):4-34. [5] Philip F, Blackstone E, Kapadia SR. Impact of statins and beta-blocker therapy on mortality after coronary artery bypass graft surgery[J].Cardiovasc Diagn Ther,2015,5(1):8-16. [6] Saxon DR, Eckel RH. Statin Intolerance: A Literature Review and Management Strategies [J]. Prog Cardiovasc Dis, 2016,59(2):153-164. [7] Lakey WC, Greyshock NG, Kelley CE, et al. Statin intolerance in a referral lipid clinic[J]. J Clin Lipidol, 2016,10(4):870-879. [8] Hata M, Takayama T, Sezai A, et al. Efficacy of aggressive lipid controlling therapy for preventing saphenous vein graft disease[J]. Ann Thorac Surg, 2009,88(5):1440-1444. [9] 何坪, 殷跃辉. 阿托伐他汀对血管的保护作用的研究进展[J]. 临床合理用药杂志, 2011,4(8):124-126. [10] Kang S, Liu Y, Liu XB.Effects of aggressive statin therapy on patients with coronary saphenous vein bypass grafts: a systematic review and meta-analysis of randomized, controlled trials[J]. Clin Ther, 2013,35(8):1125-1136.
2020, Vol. 37 
